^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
04/05/2022
Excerpt:
Thyroid carcinoma - Papillary Carcinoma...Useful in Certain Circumstances...Cabozantinib (category 1) if progression after lenvatinib and/or sorafenib